BioLife Solutions, Inc.

BioLife Solutions, Inc.

BLFSNYSE / NASDAQHealthcareSmall cap

$38.61$0.00 (0.0%)

Last close · Data as of Oct 7, 2026

Market cap
$1.3B
P/E
-288.0x
EV / EBITDA
-109.8x
Revenue
$96.2M
Net margin
-4.8%
ROCE
-4.3%

Hidden because the last close is more than three trading days older than the latest prices of its class.

BioLife Solutions, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 7 Oct 2026 close.

1M
Stale
3M
Stale
6M
Stale
1Y
Stale
5Y
Stale
  • Hidden because the last close is more than three trading days older than the latest prices of its class.

52-week range

Day change $0.00 (0.0%) from $39 to $39 · Last close Oct 7, 2026

Best weekday to invest, historically

The same weekly amount in BLFS, bought on each weekday since 2021.

News & filings

What BioLife Solutions filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 4.6 million US dollars in fiscal 2025.

Strengths (1)

  • The company carries almost no debt: debt to equity of 0.05.
  • Prices are as of 7 Oct 2026; price-based points are paused until newer prices arrive.

Prices to the 7 Oct 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Read moreShow less

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Sector
Healthcare
Shares outstanding
48.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.3B
P/E
-288.0x
P/B
3.6x
EV / EBITDA
-109.8x
EV / Sales
13.6x
P/S
13.8x
52-week high
$39.22
52-week low
$18.15

Profitability

Operating margin
-17.3%
Net margin
-4.8%
EBITDA margin
-12.4%
ROE
-1.2%
ROCE
-4.3%
ROA
-1.1%
Asset turnover
0.24

Growth

Revenue
$96.2M
Revenue growth, 1Y
28.9%
Revenue CAGR, 3Y
8.1%
Net profit growth, 1Y
-77.2%
Free cash flow
$416.0k

Solvency

Current ratio
5.94
Debt / Equity
0.05
Debt / Assets
0.04
CFO / Net profit
-4.38
Cash / Market cap
2.5%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$96.2M
Cost of revenue$34.1M
Gross profit$62.1M
Operating expenses$78.7M
Research and development$23.1M
Selling, general and administrative$55.4M
Operating income-$16.6M
Interest and other$4.5M
Pretax income-$12.1M
Tax and other-$7.5M
Net income-$4.6M

Revenue and net profit

Revenue grew 28.9% in FY2025; net profit is the dashed line.

BioLife Solutions, Inc. revenue and net profit by fiscal year
BioLife Solutions, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$76.2M-$139.8M
FY2023$68.0M-$68.0M
FY2024$74.6M-$20.2M
FY2025$96.2M-$4.6M

Cash flows

FY2025: $20.1M from operations, $416.0k free after investment (dashed).

BioLife Solutions, Inc. operating and free cash flow by fiscal year
BioLife Solutions, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$8.5M-$18.9M
FY2023-$12.5M-$18.9M
FY2024$8.4M$4.9M
FY2025$20.1M$416.0k

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$96.2M+28.9%1Y
EBITDA
-$11.9M-384.8%1Y
Net profit
-$4.6M
Cash from operations
$20.1M+138.6%1Y
Free cash flow
$416.0k-91.5%1Y
Revenue CAGR, 3Y
8.1%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$96.2M-$11.9M-$4.6M$416.0k-1.2%+28.9%-77.2%

Monthly returns

Month-by-month returns of BLFS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$405.9M
Liabilities$34.0M
Equity$371.9M
Paid-in capital$711.4M
Retained earnings-$339.7M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; BLFS highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. BioLife Solutions, Inc. (this company)13.6x

Not shown (no positive earnings and no EV / Sales): Bicara Therapeutics Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
BioLife Solutions, Inc.BLFSthis company$1.3B-288.0x3.6x-1.2%-109.8x
UroGen Pharma Ltd.URGN$1.3B-8.8x-12.7x145.5%-10.0x
Bicara Therapeutics Inc.BCAX$1.3B-9.7x3.3x-34.4%-8.0x
Inhibrx Biosciences, Inc.INBX$1.3B-9.6x167.5x-1752.2%-10.5x
Ardelyx, Inc.ARDX$1.3B-21.7x8.0x-36.9%-50.5x
Tandem Diabetes Care, Inc.TNDM$1.3B-6.5x8.6x-131.9%-9.6x
AdaptHealth Corp.AHCO$1.3B-18.7x0.9x-4.7%6.6x
Teladoc Health, Inc.TDOC$1.3B-6.6x1.0x-14.5%9.8x
Enovis CorporationENOV$1.3B-1.1x0.9x-79.5%-3.2x
Peer median—-9.2x2.1x-35.6%-8.8x

Year-to-date ROI

BLFS since 1 January, against earlier years.

Historical volatility

BLFS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

BioLife Solutions, Inc. operating margin by fiscal year
BioLife Solutions, Inc. operating margin by fiscal year
DateOperating margin
FY2022-14.0%
FY2023-28.5%
FY2024-6.0%
FY2025-17.3%
LineFY2025
Cost of revenueCost Of Revenue$34.1M
Gross profitGross Profit$62.1M
Operating expensesOperating Expense$78.7M
Research and developmentResearch And Development$23.1M
Depreciation and amortisationDepreciation And Amortization In Income Statement$260.0k
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$260.0k
Amortization$260.0k
Amortisation of intangiblesAmortization Of Intangibles Income Statement$260.0k
Total expensesTotal Expenses$112.8M
Pretax incomePretax Income-$12.1M

Learn while you research

Academy chapters picked for BioLife Solutions, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing29% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →